• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC TO-T filed by Turnstone Biologics Corp.

    7/11/25 6:05:38 AM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TSBX alert in real time by email
    SC TO-T 1 d886322dsctot.htm SC TO-T SC TO-T
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE TO

    TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

     

    TURNSTONE BIOLOGICS CORP.

    (Name of Subject Company (Issuer))

     

     

    XOMA ROYALTY CORPORATION

    (Name of Filing Persons (Offeror))

     

     

    Common Stock, Par Value $0.001 Per Share

    (Title of Class of Securities)

     

     

    98419J206

    (CUSIP Number of Class of Securities)

     

     

    Owen Hughes

    XOMA Royalty Corporation

    2200 Powell Street, Suite 310

    Emeryville, California 94608

    Tel. (510) 204-7200

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)

     

     

    Copies to:

    Ryan A. Murr

    Branden C. Berns

    Melanie E. Neary

    Gibson, Dunn & Crutcher LLP

    One Embarcadero Center, Suite 2600

    San Francisco, CA 94111

     

     

     

    ☐ 

    Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

    Check the appropriate boxes below to designate any transactions to which the statement relates:

     

    ☒ 

    third-party tender offer subject to Rule 14d-1.

     

    ☐ 

    issuer tender offer subject to Rule 13e-4.

     

    ☐ 

    going-private transaction subject to Rule 13e-3.

     

    ☐ 

    amendment to Schedule 13D under Rule 13d-2.

    Check the following box if the filing is a final amendment reporting the results of the tender offer. ☐

    If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

     

    ☐ 

    Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

     

    ☐ 

    Rule 13d-1(d) (Cross-Border Third-Party Tender Offer)

     

     
     


    This Tender Offer Statement on Schedule TO (this “Schedule TO”) relates to the offer (the “Offer”) by XOMA Royalty Corporation, a Nevada corporation (“Purchaser”), to purchase all of the outstanding shares of common stock, par value $0.001 per share (“Shares”), of Turnstone Biologics Corp., a Delaware corporation (“Turnstone”), for a price per Share of (i) $0.34 (the “Cash Amount”), payable subject to any applicable tax withholding and without interest, and (ii) one non-transferable contractual contingent value right (“CVR”) for each Share, which shall represent the right to receive potential payments, in cash, described in, and subject to and in accordance with the terms and conditions of, the CVR Agreement (as described below), subject to any applicable tax withholding and without interest (such amount, the “CVR Amount,” and together with the Cash Amount, the “Offer Price”), all upon the terms and subject to the conditions described in the Offer to Purchase, dated July 11, 2025 (together with any amendments or supplements thereto, the “Offer to Purchase”) and in the related Letter of Transmittal, copies of which are attached hereto as exhibits (a)(1)(A) and (a)(1)(B), respectively. The Offer is being made pursuant to the Agreement and Plan of Merger, dated as of June 26, 2025 (together with any amendments or supplements thereto, the “Merger Agreement”), among Turnstone, Purchaser and XRA 3 Corp., a Delaware corporation and a wholly owned subsidiary of Purchaser (“Merger Sub”), a copy of which is filed as Exhibit (d)(1) hereto and incorporated herein by reference with respect to Items 4 through 11 of this Schedule TO. Capitalized terms used but not otherwise defined herein have the meanings ascribed thereto in the Offer to Purchase.

    All of the information set forth in the Offer to Purchase is incorporated by reference herein in response to Items 1 through 9 and Item 11 of this Schedule TO, and is supplemented by the information specifically provided in this Schedule TO.

     

    ITEM 1.

    SUMMARY TERM SHEET.

    The information set forth in the section of the Offer to Purchase titled “Summary Term Sheet” is incorporated herein by reference.

     

    ITEM 2.

    SUBJECT COMPANY INFORMATION.

    The subject company and the issuer of the securities subject to the Offer is Turnstone Biologics Corp., a Delaware corporation. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and Securities Exchange Act of 1934, as amended, any stockholder communication required to be sent to Turnstone’s principal executive offices may be sent to Turnstone Biologics Corp., 9310 Athena Circle, Suite 3000, La Jolla, California 92037. Turnstone’s telephone number is (347) 897-5988.

    This Schedule TO relates to the Shares. According to Turnstone, as of the close of business on July 10, 2025, there were: (i) 23,140,691 Shares issued and outstanding, (ii) 1,856,251 Shares subject to outstanding Turnstone Stock Options and (iii) 1,135 Shares subject to outstanding Turnstone Restricted Stock Units.

    The information concerning the principal market on which the Shares are traded, and certain high and low sales prices for the Shares in the principal market in which the Shares are traded set forth in “Special Factors—Section 3. Price Range of Shares; Dividends” of the Offer to Purchase, are incorporated herein by reference.

     

    ITEM 3.

    IDENTITY AND BACKGROUND OF FILING PERSON.

    (a)–(c) The filing company of this Schedule TO is Purchaser. Purchaser’s principal executive office is located at 2200 Powell Street, Suite 310, Emeryville, California 94608. Purchaser’s telephone number is (510) 204-7200.

    Purchaser was formed under the laws of the State of Delaware on December 31, 2011 and reincorporated under the laws of the State of Nevada on May 30, 2025, and its principal business is to engage in any lawful act or activity for which corporations may be organized under the Nevada Revised Statutes. The executive officers of Purchaser are Owen Hughes, its Chief Executive Officer, Tom Burns, its Senior Vice President, Finance and Chief

    Financial Officer, and Brad Sitko, its Chief Investment Officer. Each executive officer of Purchaser is a United States citizen and has a business address located at 2200 Powell Street, Suite 310, Emeryville, California 94608.


    The information set forth in “The Tender Offer—Section 6. Certain Information Concerning Purchaser” and Schedule A—“Information Concerning Members of the Boards of Directors and the Executive Officers of Purchaser” of the Offer to Purchase is incorporated herein by reference.

     

    ITEM 4.

    TERMS OF THE TRANSACTION.

    (a)(1)(i)-(viii), (x), (xii), (a)(2)(i)-(v), (vii) The information set forth in the Offer to Purchase is incorporated herein by reference.

    (a)(1)(ix), (xi), (a)(2)(vi) Not applicable.

     

    ITEM 5.

    PAST CONTACTS, TRANSACTIONS, NEGOTIATIONS AND AGREEMENTS.

    (a), (b) The information set forth in “Special Factors—Section 1. Background of the Offer; Contacts with Turnstone,” “Special Factors—Section 2. Purpose of the Offer and Plans for Turnstone,” “The Tender Offer—Section 5. Certain Information Concerning Turnstone,” “The Tender Offer—Section 6. Certain Information Concerning Purchaser” and “Schedule A—Information Concerning Members of the Boards of Directors and the Executive Officers of Purchaser” of the Offer to Purchase is incorporated herein by reference.

     

    ITEM 6.

    PURPOSES OF THE TRANSACTION AND PLANS OR PROPOSALS.

    (a), (c)(1)–(7) The information set forth in the sections of the Offer to Purchase titled “Summary Term Sheet” and “Introduction” and in “Special Factors—Section 2. Purpose of the Offer and Plans for Turnstone,” “Special Factors—Section 3. Price Range of Shares; Dividends,” “Special Factors—Section 4. Possible Effects of the Offer on the Market for the Shares; Nasdaq Listing; Exchange Act Registration and Margin Regulations,” “The Tender Offer—Section 1. Terms of the Offer” and “The Tender Offer—Section 7. Summary of the Merger Agreement and Certain Other Agreements” of the Offer to Purchase is incorporated herein by reference.

     

    ITEM 7.

    SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

    (a), (d) The information set forth in the section of the Offer to Purchase titled “Summary Term Sheet” and in “The Tender Offer—Section 8. Source and Amount of Funds” of the Offer to Purchase is incorporated herein by reference.

    (b) The Offer is not subject to a financing condition.

     

    ITEM 8.

    INTEREST IN SECURITIES OF THE SUBJECT COMPANY.

    The information set forth in “Special Factors—Section 2. Purpose of the Offer and Plans for Turnstone,” “The Tender Offer—Section 6. Certain Information Concerning Purchaser” and “Schedule A—Information Concerning Members of the Boards of Directors and the Executive Officers of Purchaser” of the Offer to Purchase and “Item 3—Identity and Background of the Filing Person” hereof is incorporated herein by reference.

     

    ITEM 9.

    PERSONS/ASSETS RETAINED, EMPLOYED, COMPENSATED OR USED.

    (a) The information set forth in the section of the Offer to Purchase titled “Introduction” and in “Special Factors—Section 1. Background of the Offer; Contacts with Turnstone,” “The Tender Offer—Section 3. Procedures for Tendering Shares” and “The Tender Offer—Section 12. Fees and Expenses” of the Offer to Purchase is incorporated herein by reference.


    ITEM 10.

    FINANCIAL STATEMENTS.

    Not applicable. Pursuant to Instruction 2 to Item 10 of Schedule TO, Purchaser’s financial statements are not considered material because (i) the consideration offered consists solely of cash, (ii) the Offer is not subject to any financing condition and (iii) Purchaser is a public reporting company under Section 13(a) or 15(d) of the Act that files reports electronically on EDGAR.

     

    ITEM 11.

    ADDITIONAL INFORMATION.

    (a) The information set forth in “Special Factors—Section 1. Background of the Offer; Contacts with Turnstone,” “Special Factors—Section 2. Purpose of the Offer and Plans for Turnstone,” “Special Factors—Section 4. Possible Effects of the Offer on the Market for the Shares; Nasdaq Listing; Exchange Act Registration and Margin Regulations,” “The Tender Offer—Section 6. Certain Information Concerning Purchaser,” “The Tender Offer—Section 7. Summary of the Merger Agreement and Certain Other Agreements” and “The Tender Offer—Section 11. Certain Legal Matters; Regulatory Approvals” of the Offer to Purchase is incorporated herein by reference.

    (c) The information set forth in the Offer to Purchase is incorporated herein by reference.

     

    ITEM 12.

    EXHIBITS.

     

    Index No.

       
    (a)(1)(A)*   Offer to Purchase, dated July 11, 2025.
    (a)(1)(B)*   Form of Letter of Transmittal.
    (a)(1)(C)*   Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
    (a)(1)(D)*   Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
    (a)(5)(A)   Press Release of Turnstone issued on June 27, 2025 (incorporated by reference to Exhibit  99.1 to Turnstone’s Current Report on Form 8-K filed with the SEC on June 27, 2025).
    (d)(1)   Agreement and Plan of Merger, by and among XOMA Royalty Corporation, XRA 3 Corp. and Turnstone Biologics Corp., dated June  26, 2025 (incorporated by reference to Exhibit 2.1 to Turnstone’s Current Report on Form 8-K filed with the SEC on June 27, 2025).
    (d)(2)*   Confidentiality Agreement dated April 16, 2025 between Turnstone and Purchaser.
    (d)(3)   Form of Contingent Value Rights Agreement (incorporated herein by reference to Exhibit C of Exhibit 2.1 to Turnstone’s Current Report on Form 8-K/A filed with the SEC on July 1, 2025).
    (d)(4)   Form of Tender and Support Agreement (incorporated herein by reference to Exhibit D of Exhibit 2.1 to Turnstone’s Current Report on Form 8-K/A filed with the SEC on July 1, 2025).
    (g)   Not applicable.
    (h)   Not applicable.
    107*   Filing Fee Table.

     

    *

    Filed herewith.

     

    ITEM 13.

    INFORMATION REQUIRED BY SCHEDULE 13E-3.

    Not applicable.


    SIGNATURE

    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: July 11, 2025

     

    XOMA Royalty Corporation
    By:  

    /s/ Owen Hughes

      Name: Owen Hughes
      Title: Chief Executive Officer
    Get the next $TSBX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TSBX

    DatePrice TargetRatingAnalyst
    2/5/2025$3.75 → $0.40Overweight → Neutral
    Piper Sandler
    11/15/2024Neutral → Underperform
    BofA Securities
    10/14/2024Buy → Neutral
    BofA Securities
    8/16/2023Market Perform
    SVB Securities
    8/15/2023$20.00Overweight
    Piper Sandler
    8/15/2023$18.00Buy
    BofA Securities
    More analyst ratings

    $TSBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Turnstone Biologics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Turnstone Biologics from Overweight to Neutral and set a new price target of $0.40 from $3.75 previously

      2/5/25 8:04:09 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics downgraded by BofA Securities

      BofA Securities downgraded Turnstone Biologics from Neutral to Underperform

      11/15/24 8:23:44 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics downgraded by BofA Securities

      BofA Securities downgraded Turnstone Biologics from Buy to Neutral

      10/14/24 7:44:47 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

      EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced that they have entered into a definitive merger agreement ("the Merger Agreement"), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock ("Turnstone common stock") plus one non-transferable contingent value right ("CVR"). Following a thorough review process conducted with the assistance of its legal and financial advisors, the Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best

      6/27/25 7:30:00 AM ET
      $TSBX
      $XOMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights

      SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates. Corporate Updates In January 2025, Turnstone made the determination to discontinue all TIDAL-01 clinical studies and halted further development of the program. As a result, the Company initiated a process to explore a range of potentia

      5/8/25 6:00:49 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. Corporate Updates In November 2024, the Company presented preclinical data on its Selected TIL therapies at the 2024 Society for Immunotherapy of Cancer ("SITC") Annual Meeting. Turnstone also presented clinical data at t

      3/28/25 9:03:57 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    SEC Filings

    See more
    • Amendment: SEC Form SC 14D9/A filed by Turnstone Biologics Corp.

      SC 14D9/A - Turnstone Biologics Corp. (0001764974) (Subject)

      7/17/25 4:37:10 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form 8-K/A filed by Turnstone Biologics Corp.

      8-K/A - Turnstone Biologics Corp. (0001764974) (Filer)

      7/17/25 4:15:41 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 14D9 filed by Turnstone Biologics Corp.

      SC 14D9 - Turnstone Biologics Corp. (0001764974) (Subject)

      7/11/25 7:05:49 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Gould Robert J

      4 - Turnstone Biologics Corp. (0001764974) (Issuer)

      7/2/24 4:45:14 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Gupta Rishi

      4 - Turnstone Biologics Corp. (0001764974) (Issuer)

      7/2/24 4:45:12 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Rajangam Kanya

      4 - Turnstone Biologics Corp. (0001764974) (Issuer)

      7/2/24 4:45:15 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    Leadership Updates

    Live Leadership Updates

    See more
    • Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

      SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. "We are excited about the therapeutic potential of our pipeline of next-generation Selected TIL therapies," said Sammy Farah, M.B.A., Ph.D., Turnstone's President and Chief Executive Officer. "The next frontier for TIL therapy is to extend its therapeutic activity

      5/13/24 5:01:26 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics Appoints William Waddill to its Board of Directors

      SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,

      4/16/24 9:00:00 AM ET
      $ANNX
      $ARWR
      $PTGX
      $TSBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

      Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone's novel Selected TIL programs for solid tumors presented at SITC 2023 Further strengthened Scientific Advisory Board with appointment of internationally recognized cancer immunotherapy expert, Dr. Jeffrey S. Weber SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported

      3/21/24 5:06:41 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    Financials

    Live finance-specific insights

    See more
    • Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

      EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced that they have entered into a definitive merger agreement ("the Merger Agreement"), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock ("Turnstone common stock") plus one non-transferable contingent value right ("CVR"). Following a thorough review process conducted with the assistance of its legal and financial advisors, the Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best

      6/27/25 7:30:00 AM ET
      $TSBX
      $XOMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. Corporate Updates In November 2024, the Company presented preclinical data on its Selected TIL therapies at the 2024 Society for Immunotherapy of Cancer ("SITC") Annual Meeting. Turnstone also presented clinical data at t

      3/28/25 9:03:57 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Turnstone Biologics Corp. (Amendment)

      SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)

      5/31/24 4:23:52 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Turnstone Biologics Corp. (Amendment)

      SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)

      4/29/24 8:22:22 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Turnstone Biologics Corp.

      SC 13G - Turnstone Biologics Corp. (0001764974) (Subject)

      3/18/24 9:13:28 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care